Clinical outcome of CIDP one year after start of treatment: a prospective cohort study

Objective To assess clinical outcome in treatment-naive patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods We included adult treatment-naive patients participating in the prospective International CIDP Outcome Study (ICOS) that fulfilled the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) diagnostic criteria for CIDP. Patients were grouped based on initial treatment with (1) intravenous immunoglobulin (IVIg), (2) corticosteroid monotherapy or (3) IVIg and corticosteroids (combination treatment). Outcome measures included the inflammatory Rasch-built overall disability scale (I-RODS), grip strength, and Medical Research Council (MRC) sum score. Treatment response, treatment status, remissions (improved and untreated), treatment changes, and residual symptoms or deficits were assessed at 1 year. Results Forty patients were included of whom 18 (45%) initially received IVIg, 6 (15%) corticosteroids, and 16 (40%) combination treatment. Improvement on ≥ 1 of the outcome measures was seen in 31 (78%) patients. At 1 year, 19 (48%) patients were still treated and fourteen (36%) patients were in remission. Improvement was seen most frequently in patients started on IVIg (94%) and remission in those started on combination treatment (44%). Differences between groups did not reach statistical significance. Residual symptoms or deficits ranged from 25% for neuropathic pain to 96% for any sensory deficit. Conclusions Improvement was seen in most patients. One year after the start of treatment, more than half of the patients were untreated and around one-third in remission. Residual symptoms and deficits were common regardless of treatment..

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:269

Enthalten in:

Journal of neurology - 269(2021), 2 vom: 26. Juni, Seite 945-955

Sprache:

Englisch

Beteiligte Personen:

Bus, S. R. M. [VerfasserIn]
Broers, M. C. [VerfasserIn]
Lucke, I. M. [VerfasserIn]
Bunschoten, C. [VerfasserIn]
van Lieverloo, G. G. A. [VerfasserIn]
Adrichem, M. E. [VerfasserIn]
van Veen, R. [VerfasserIn]
Wieske, L. [VerfasserIn]
Lingsma, H. F. [VerfasserIn]
Goedee, H. S. [VerfasserIn]
van der Pol, W. L. [VerfasserIn]
van Schaik, I. N. [VerfasserIn]
Van Doorn, P. A. [VerfasserIn]
Jacobs, B. C. [VerfasserIn]
Eftimov, F. [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

CIDP
Chronic inflammatory demyelinating polyradiculoneuropathy
Corticosteroids
Intravenous immunoglobulin

RVK:

RVK Klassifikation

Anmerkungen:

© The Author(s) 2021

doi:

10.1007/s00415-021-10677-5

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2129146244

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?